Nano Dimension Ltd. Form 8-K Filing

Nano Dimension Ltd. (Nano) has issued a press release on June 16, 2026, providing further details regarding its proposed business combination with Infinite Epigenetics, Inc. The company addresses concerns raised by Murchinson Ltd., emphasizing that Infinite Epigenetics is an established business with operating units, CLIA-certified laboratories, and proprietary assets in the epigenetics field. The press release highlights the scientific validity of epigenetics and compares Infinite Epigenetics' business model to successful public companies in the molecular diagnostics space. Nano's Board of Directors believes this combination offers a significant long-term value creation opportunity by transitioning Nano's operations to AI-powered preventive health and diagnostics, targeting a large addressable market. The capital from this transaction is intended to accelerate the commercialization of Infinite's diagnostics and the development of its AI platform, leveraging proprietary biological data. The company contrasts this transaction with SPACs, emphasizing its focus on a defined operating business and value accretion for existing shareholders. Nano Dimension also outlines its rigorous review process, board expertise, and alignment with shareholder interests, while refuting claims of misaligned motivations. The company details its strategy to deploy capital for clinical validation, commercial growth, and AI platform development, emphasizing the recurring revenue model of epigenetic testing and the compounding value of its data and AI capabilities. The press release also includes forward-looking statements, risk factors, and information on where to find additional details regarding the proposed combination and related solicitations.